ISSN 2997-1036
International Journal of Hematology | Vol. 13, No. 7, June 2022 | pp. 49–56
DOI: 10.46882/2022/IJH/000149
Original Article
Title: Immunophenotypic profile and clinical stage stratification of B-cell chronic lymphoproliferative disorders utilizing CD200 and CD306 expression markers
Names of Authors: W. A. Adebayo¹, X. Y. Emeka², Z. Z. Salami³
Authors’ Affiliations: ¹Department of Haematology, University of Ibadan, Ibadan, Nigeria; ²Department of Haematology, University of Calabar Teaching Hospital, Calabar, Nigeria; ³Department of Pathology, Lagos University Teaching Hospital, Lagos, Nigeria
Abstract: Multiparameter flow cytometry immunophenotyping plays an important role in separating overlapping mature B-cell malignancies. This prospective study evaluated the diagnostic performance of combining CD200 and CD306 (LAIR2) markers to differentiate chronic lymphocytic leukemia from mantle cell lymphoma and marginal zone lymphoma in 55 adult patients presenting with persistent absolute lymphocytosis. Lineage markers and monoclonal light chain restriction were established using flow cytometry. Chronic lymphocytic leukemia was confirmed in 38 cases, while 17 were diagnosed with non-CLL mature B-cell variants. Strong, uniform surface expression of CD200 paired with positive CD306 was detected in 94.7% (36 of 38) of the chronic lymphocytic leukemia cases. In contrast, mantle cell lymphoma cohorts demonstrated a complete absence of CD200 alongside dim or negative CD306 and bright CD20 expression (P < 0.001). Marginal zone lymphoma variants exhibited variable CD306 paired with negative or dim CD200 parameters. High expression density for CD200 correlated with early clinical presentation (Binet Stage A). Incorporating CD200 and CD306 into standard screening protocols provides excellent diagnostic specificity, reducing borderline scores and helping classify mature B-cell expansions.
Keywords: Chronic lymphocytic leukemia, CD200, CD306, flow cytometry, lymphoproliferative disorders, immunophenotyping
Manuscript Timeline: Received: April 14, 2022; Revised: May 20, 2022; Accepted: June 08, 2022; Published: June 20, 2022